Novartis
Novartis swine-flu jab effective in single dose
September 3, 2009Manufacturing and Production, Research and Development, Sales and Marketing Novartis, h1n1
A study of Novartis' pandemic swine-flu jab shows it is potentially protective after just one dose, which could help eke …
UCB and Novartis expand alliance in Germany
September 1, 2009Sales and Marketing Germany, Novartis, UCB
UCB and Novartis have extended their partnership in Germany with a new licensing deal for the cardiovascular and diabetes drug …
Novartis unveils new lab approach to boost research capacity
August 27, 2009Research and Development Novartis, Switzerland
Novartis has unveiled a new research approach involving novel lab technology and flexible working, in the hope to speed its …
Novartis’ Extavia approved in US
August 19, 2009Research and Development, Sales and Marketing Extavia, MS, Novartis
Novartis has received US approval for its betaferon product for multiple sclerosis.Extavia’s active ingredient is interferon beta-1b, putting it into …
Animal rights attacks were terrorism not activism, says Vasella
August 13, 2009Research and Development, Sales and Marketing Animal tests, Novartis, Vasella
Novartis chief executive Daniel Vasella has spoken for the first time of his shock at the arson attack on his …
Vasella targeted by animal rights activists
August 6, 2009Research and Development, Sales and Marketing Animal tests, Novartis, Vasella
Animal rights activists are believed to be behind two attacks on Novartis chief executive Daniel Vasella. The first attack came …
Afinitor approved in EU
August 6, 2009Research and Development, Sales and Marketing Afinitor, Cancer, Europe, Novartis
Novartis’ new kidney cancer drug Afinitor (everolimus) has been approved in the EU for use when products such as Sutent …
Novartis extends TB donation
July 14, 2009Sales and Marketing Africa, Novartis, TB
Novartis has extended its tuberculosis (TB) drug donation programme to Tanzania. Novartis has already delivered nearly 250,000 TB treatments to …
Novartis and NHS Alliance collaborate on commissioning guides
July 14, 2009Sales and Marketing NHS, Novartis, PBC
Novartis has teamed up with the NHS Alliance to launch a series of guides to help practice-based commissioning leaders tackle …
Vasella: on leadership
July 7, 2009Sales and Marketing Novartis, Vasella, leadership, management
Novartis’ chief executive and chairman talks to McKinsey about his personal approach to management and leadership, and examines subjects including …
Novartis gains approval for first Japanese biosimilar
June 25, 2009Research and Development, Sales and Marketing Novartis, generics
Japan has approved its first biosimilar medicine – the recombinant human growth hormone somatropin from Novartis' generic arm Sandoz. The …
Novartis cooks up first swine flu vaccine batch
June 16, 2009Manufacturing and Production Novartis
Novartis is ready to press ahead with clinical trials of its candidate vaccine against influenza (A)H1N1, having completed manufacturing of …
Strong prospects for Novartis cancer drug, say analysts
April 24, 2009Research and Development, Sales and Marketing Afinitor, Novartis
The FDA has approved Novartis's Afinitor for advanced renal cell carcinoma patients who have progressed after first-line Sutent or Nexavar …
Novartis boasts strong sales for 2008
February 11, 2009Sales and Marketing Novartis
Novartis has weathered the financial downturn and delivered a strong performance for 2008. Overall group sales were boosted by 9% …
Novartis boosts vaccine pipeline
January 8, 2009Research and Development, Sales and Marketing Novartis, recruitment, vaccines
Novartis has added an investigational vaccine to its pipeline through a $20 million deal with AlphaVax. The North Carolina-based biotech …
